Investigative analysis highlights the immunomodulatory effects of zinc oxide nanoparticles in cancer therapies, suggesting clinical potential.
Crucially, ZnO demonstrates a strong immunomodulatory capability, promoting T-cell activation and dendritic cell maturation necessary to reverse the 'cold' tumor microenvironment often associated with solid and deep-seated tumors. Overall, ZnO NPs offer revolutionary therapeutic prospects for novel anti-cancer treatments, provided that challenges regarding long-term stability and controlled degradability are addressed in future works for clinical translation.
No takes yet. Share an insight, caveat, or question.
Conte et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: